Alberta Investment Management Corp bought a new position in shares of argenx SE (NASDAQ:ARGX – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,163 shares of the company’s stock, valued at approximately $3,909,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of ARGX. Evolutionary Tree Capital Management LLC lifted its stake in shares of argenx by 57.0% in the fourth quarter. Evolutionary Tree Capital Management LLC now owns 24,196 shares of the company’s stock valued at $8,473,000 after buying an additional 8,786 shares in the last quarter. Ensign Peak Advisors Inc lifted its stake in shares of argenx by 96.5% in the fourth quarter. Ensign Peak Advisors Inc now owns 18,520 shares of the company’s stock valued at $6,485,000 after buying an additional 9,097 shares in the last quarter. Parkwood LLC bought a new position in shares of argenx in the fourth quarter valued at $240,000. Berry Street Capital Management LLP bought a new position in shares of argenx in the fourth quarter valued at $3,502,000. Finally, Pictet Asset Management SA lifted its stake in shares of argenx by 6.4% in the fourth quarter. Pictet Asset Management SA now owns 363,260 shares of the company’s stock valued at $127,210,000 after buying an additional 21,856 shares in the last quarter. 58.76% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have recently commented on ARGX shares. Morgan Stanley upgraded shares of argenx from an “equal weight” rating to an “overweight” rating and set a $375.00 target price for the company in a report on Tuesday, May 3rd. JPMorgan Chase & Co. increased their target price on shares of argenx from €350.00 ($372.34) to €370.00 ($393.62) and gave the company an “overweight” rating in a report on Friday, May 6th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “hold” rating to a “buy” rating in a report on Friday, May 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of argenx in a report on Friday, March 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, argenx currently has an average rating of “Buy” and a consensus price target of $360.94.
argenx (NASDAQ:ARGX – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported ($4.36) earnings per share for the quarter, topping the consensus estimate of ($5.08) by $0.72. argenx had a negative net margin of 147.47% and a negative return on equity of 32.54%. During the same period in the prior year, the business earned ($0.81) earnings per share. On average, research analysts expect that argenx SE will post -19.44 earnings per share for the current year.
About argenx (Get Rating)
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.
- Get a free copy of the StockNews.com research report on argenx (ARGX)
- Dentsply Stock is Repricing Itself
- Is Zoom Video (NASDAQ: ZM) Starting To Bottom Out?
- Short-Covering Begins In Big Lots
- Institutions Ring The Register On Toll Brothers Stock
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.